Unknown

Dataset Information

0

Pharmacology in translation: the preclinical and early clinical profile of the novel ?2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.


ABSTRACT: BACKGROUND AND PURPOSE:Benzodiazepines, non-selective positive allosteric modulators (PAMs) of GABAA receptors, have significant side effects that limit their clinical utility. As many of these side effects are mediated by the ?1 subunit, there has been a concerted effort to develop ?2/3 subtype-selective PAMs. EXPERIMENTAL APPROACH:In vitro screening assays were used to identify molecules with functional selectivity for receptors containing ?2/3 subunits over those containing ?1 subunits. In vivo receptor occupancy (RO) was conducted, prior to confirmation of in vivo ?2/3 and ?1 pharmacology through quantitative EEG (qEEG) beta frequency and zolpidem drug discrimination in rats respectively. PF-06372865 was then progressed to Phase 1 clinical trials. KEY RESULTS:PF-06372865 exhibited functional selectivity for those receptors containing ?2/3/5 subunits, with significant positive allosteric modulation (90-140%) but negligible activity (?20%) at GABAA receptors containing ?1 subunits. PF-06372865 exhibited concentration-dependent occupancy of GABAA receptors in preclinical species. There was an occupancy-dependent increase in qEEG beta frequency and no generalization to a GABAA ?1 cue in the drug-discrimination assay, clearly demonstrating the lack of modulation at the GABAA receptors containing an ?1 subtype. In a Phase 1 single ascending dose study in healthy volunteers, evaluation of the pharmacodynamics of PF-06372865 demonstrated a robust increase in saccadic peak velocity (a marker of ?2/3 pharmacology), increases in beta frequency qEEG and a slight saturating increase in body sway. CONCLUSIONS AND IMPLICATIONS:PF-06372865 has a unique clinical pharmacology profile and a highly predictive translational data package from preclinical species to the clinical setting.

SUBMITTER: Nickolls SA 

PROVIDER: S-EPMC5786456 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABA<sub>A</sub> receptor positive allosteric modulator PF-06372865.

Nickolls Sarah A SA   Gurrell Rachel R   van Amerongen Guido G   Kammonen Juha J   Cao Lishuang L   Brown Adam R AR   Stead Clara C   Mead Andy A   Watson Christine C   Hsu Cathleen C   Owen Robert M RM   Pike Andy A   Fish Rebecca L RL   Chen Laigao L   Qiu Ruolun R   Morris Evan D ED   Feng Gang G   Whitlock Mark M   Gorman Donal D   van Gerven Joop J   Reynolds David S DS   Dua Pinky P   Butt Richard P RP  

British journal of pharmacology 20180118 4


<h4>Background and purpose</h4>Benzodiazepines, non-selective positive allosteric modulators (PAMs) of GABA<sub>A</sub> receptors, have significant side effects that limit their clinical utility. As many of these side effects are mediated by the α1 subunit, there has been a concerted effort to develop α2/3 subtype-selective PAMs.<h4>Experimental approach</h4>In vitro screening assays were used to identify molecules with functional selectivity for receptors containing α2/3 subunits over those con  ...[more]

Similar Datasets

| S-EPMC4931879 | biostudies-other
| S-EPMC8032764 | biostudies-literature
| S-EPMC6146053 | biostudies-literature
| S-EPMC6420870 | biostudies-literature
| S-EPMC1576032 | biostudies-other
| S-EPMC4789665 | biostudies-literature
| S-EPMC8359322 | biostudies-literature
| S-EPMC4789672 | biostudies-literature
| S-EPMC4018048 | biostudies-literature
| S-EPMC5969218 | biostudies-literature